Related Experiment Video

Updated: Jul 18, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular

Paul S Chan1, Theodore Chow, Dean Kereiakes

  • 1Division of Cardiology, University of Michigan, Ann Arbor, USA. paulchan@umich.edu

Archives of Internal Medicine
|November 15, 2006
PubMed

Insights

Implantable cardioverter-defibrillators (ICDs) reduce all-cause mortality in patients with ischemic heart disease. This study confirms ICDs

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Implantable cardioverter-defibrillators (ICDs) are proven to reduce mortality in primary prevention trials for patients with ischemic heart disease and left ventricular dysfunction.
  • The generalizability of these findings to real-world clinical practice requires investigation.

Purpose of the Study:

  • To evaluate the effectiveness of implantable cardioverter-defibrillators (ICDs) in reducing mortality in a real-world clinical setting.
  • To assess the impact of ICDs on all-cause mortality and arrhythmia-related mortality in patients with ischemic left ventricular dysfunction.

Main Methods:

  • A prospective, multicenter cohort study included 770 patients with ischemic left ventricular dysfunction (ejection fraction ≤35%) and no history of ventricular arrhythmia.
  • Of the participants, 395 (52%) received ICDs, with a mean follow-up of 27 months.
  • Cox proportional hazards analyses, including propensity score analysis, were used to control for clinical predictors of death and arrhythmic events.

Main Results:

  • Patients receiving ICDs showed significantly lower all-cause mortality (HR, 0.53; 95% CI, 0.33-0.86).
  • The reduction in all-cause mortality was primarily driven by a significant decrease in arrhythmia-related mortality (HR, 0.35; 95% CI, 0.17-0.73).
  • No significant differences in cardiovascular nonarrhythmic or noncardiovascular mortality were observed between groups. Baseline risk for life-threatening arrhythmic events was similar between ICD and non-ICD groups.

Conclusions:

  • Implantable cardioverter-defibrillators (ICDs) demonstrate effectiveness in reducing all-cause and arrhythmia-related mortality in clinical practice.
  • The observed mortality reduction in real-world settings aligns with findings from primary prevention trials.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...